Is Gilead Sciences, Inc. (GILD) a Stock to Watch This Week?

Monday, September 14, 2020 11:08 AM | InvestorsObserver Analysts

Overall market sentiment has been high on Gilead Sciences, Inc. (GILD) stock lately. GILD receives a Bullish rating from InvestorsObserver's Stock Sentiment Indicator.

Sentiment Score - ,bullish
Gilead Sciences, Inc. has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on GILD!

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.

Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.

InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.

For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With GILD Stock Today?

Gilead Sciences, Inc. (GILD) stock is trading at $67.40 as of 10:52 AM on Monday, Sep 14, a rise of $2.50, or 3.85% from the previous closing price of $64.90. The stock has traded between $64.31 and $67.92 so far today. Volume today is 7,602,562 compared to average volume of 9,600,333.

To see the top 5 stocks in the Drug Manufacturers - General industry click here.

More About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Click Here to get the full Stock Score Report on Gilead Sciences, Inc. (GILD) Stock.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Sector Update: Afternoon Recovery for Health Care Stocks

Sector Update: Health Care

Where Will Celldex Therapeutics, Inc. (CLDX) Stock Go Next After It Is Up 23.13% in a Week?

Seelos Therapeutics Inc (SEEL) Stock: What Does the Chart Say?

Related Companies